PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 63 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,360,086 | -39.0% | 201,444 | +0.9% | 0.00% | 0.0% |
| Q2 2023 | $5,512,262 | +42.2% | 199,575 | +18.4% | 0.00% | 0.0% |
| Q1 2023 | $3,876,259 | +116.2% | 168,533 | +2.6% | 0.00% | – |
| Q4 2022 | $1,792,786 | +34.6% | 164,325 | +4.0% | 0.00% | – |
| Q3 2022 | $1,332,000 | +18.5% | 158,059 | +11.3% | 0.00% | – |
| Q2 2022 | $1,124,000 | -66.0% | 142,071 | +1.6% | 0.00% | -100.0% |
| Q1 2022 | $3,310,000 | -30.1% | 139,769 | +0.9% | 0.00% | 0.0% |
| Q4 2021 | $4,736,000 | +103.8% | 138,494 | +5.6% | 0.00% | – |
| Q3 2021 | $2,324,000 | -64.6% | 131,133 | -10.4% | 0.00% | -100.0% |
| Q2 2021 | $6,567,000 | +89.8% | 146,330 | +9.5% | 0.00% | 0.0% |
| Q1 2021 | $3,460,000 | +32.7% | 133,595 | +3.3% | 0.00% | 0.0% |
| Q4 2020 | $2,607,000 | +41.1% | 129,304 | +36.9% | 0.00% | – |
| Q3 2020 | $1,847,000 | +3.2% | 94,454 | -6.8% | 0.00% | – |
| Q2 2020 | $1,790,000 | +203.4% | 101,352 | +21.3% | 0.00% | – |
| Q1 2020 | $590,000 | +0.2% | 83,583 | +0.0% | 0.00% | – |
| Q4 2019 | $589,000 | -36.7% | 83,582 | +8.0% | 0.00% | – |
| Q3 2019 | $930,000 | -26.2% | 77,402 | -25.6% | 0.00% | – |
| Q2 2019 | $1,261,000 | +59.2% | 104,088 | +65.1% | 0.00% | – |
| Q1 2019 | $792,000 | +85.9% | 63,036 | -0.4% | 0.00% | – |
| Q4 2018 | $426,000 | -34.6% | 63,269 | 0.0% | 0.00% | – |
| Q3 2018 | $651,000 | +52.8% | 63,269 | 0.0% | 0.00% | – |
| Q2 2018 | $426,000 | -0.9% | 63,269 | +26.6% | 0.00% | – |
| Q1 2018 | $430,000 | -53.5% | 49,966 | +12.4% | 0.00% | – |
| Q4 2017 | $925,000 | +80.3% | 44,473 | +53.0% | 0.00% | – |
| Q3 2017 | $513,000 | +63.9% | 29,061 | +5.2% | 0.00% | – |
| Q2 2017 | $313,000 | -6.6% | 27,626 | +5.7% | 0.00% | – |
| Q1 2017 | $335,000 | -33.0% | 26,148 | +15.1% | 0.00% | – |
| Q4 2016 | $500,000 | +66.1% | 22,715 | +59.9% | 0.00% | – |
| Q3 2016 | $301,000 | – | 14,202 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $26,721 | 7.77% |
| Bain Capital Life Sciences Investors, LLC | 2,364,410 | $25,796 | 2.88% |
| Sio Capital Management, LLC | 434,635 | $4,741,868 | 1.75% |
| Tri Locum Partners LP | 199,500 | $2,177,000 | 0.88% |
| Kynam Capital Management, LP | 520,922 | $5,683,259 | 0.87% |
| RTW INVESTMENTS, LP | 3,591,986 | $39,188,567 | 0.80% |
| Madison Avenue Partners, LP | 406,593 | $4,435,930 | 0.79% |
| Deep Track Capital, LP | 871,493 | $9,507,989 | 0.40% |
| Soleus Capital Management, L.P. | 236,000 | $2,574,760 | 0.37% |
| BRAIDWELL LP | 927,800 | $10,122,298 | 0.34% |